Timing and durability of response to erenumab in patients with chronic migraine-Reference-Cited by-同舟云学术

Timing and durability of response to erenumab in patients with chronic migraine

Published:2021-08-07 Issue:8 Volume:61 Page:1255-1263
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache

Author:

Tepper Stewart J.¹,Lucas Sylvia²,Ashina Messoud³^ORCID,Schwedt Todd J.⁴,Ailani Jessica⁵,Scanlon James⁶,Klatt Jan⁷,Chou Denise E.⁶,Wang Andrea⁶,Paiva da Silva Lima Gabriel⁶

Affiliation:

1. Geisel School of Medicine at Dartmouth Hanover NH USA

2. University of Washington Medical Center Seattle WA USA

3. Danish Headache Center University of Copenhagen Copenhagen Denmark

4. Mayo Clinic Phoenix AZ USA

5. Medstar Georgetown University Washington DC USA

6. Amgen Inc. Thousand Oaks CA USA

7. Novartis Basel Switzerland

Funder

Amgen

Novartis

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.14193

Reference19 articles.

1. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

2. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment

3. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

4. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE;Neurology and Therapy;2023-10-04

2. Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome;European Journal of Neurology;2023-04-26

3. Erenumab efficacy in migraine headache prophylaxis: A systematic review;International Immunopharmacology;2023-04

4. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study;Frontiers in Neurology;2023-03-22

5. An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor;European Journal of Neurology;2023-03-15